All In Biotech

Drug Trial Radar · NCT01728467

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

Phase 2 Randomised, Double-blind, Placebo-controlled, Cross-over Study for the Assessment of Glucose Metabolism Changes With RVX000222 in Individuals With Pre-diabetes

Last checked: Nov 19, 2026Latest source record: Apr 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Nov 2012

Primary completion

Mar 2014

Study completion Mar 2014

Sponsor

Lead sponsor
Resverlogix CorpIndustry
Sponsor type
Industry
Collaborators
Baker Heart and Diabetes Institute; Nucleus Network Ltd
First posted
Nov 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study builds on data that high-density lipoprotein (HDL) has a number of potentially beneficial effects including directly modulating glucose metabolism through multiple mechanisms. The primary objective of this study is to determine the effects of RVX000222 on postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test (OGTT).

Conditions

  • Diabetes

Interventions

  • RVX000222Drug

    capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days

  • Placebo, RVX000222Drug

    capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in plasma glucose following treatment with RVX000222 compared to placeboTime frame: 29-33 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Baker IDI Heart and Diabetes Institute 75 Commercial Road,

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.